What is MANE's market cap?

$5.70B, based on the Nov 4 close of $136.51.

Does Veradermics, Incorporated pay a dividend?

No regular cash dividend has been paid in the last year.

How much of MANE is sold short?

3.7M shares, 15.2% of float, as of Oct 15, 2026.

What sector is MANE in?

Healthcare, in the Pharmaceuticals industry.

NYSE · MANEHealthcarePharmaceuticals

Veradermics, Incorporated (MANE)

$136.51+2.17%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$132.63▲ 251.32% in range

Feb 4, 2026Low $37.03 · High $143.85Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Veradermics, Incorporated closed at $136.51 on Nov 4, up 2.17%, 5.1% below its highest close since Feb 4. Volume of 562.5K shares was 0.67× its 20-day average (below normal).

Split-adjusted performance: +25.3% over one month, +24.4% over six months.

Short interest was 3.7M shares at the Oct 15 settlement, down 12.9% from the prior report (15.2% of float, 3.8 days to cover).

Market cap$5.70B41.8M shares

Revenue · quarter$0.00—

Diluted EPS$-0.58—

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Feb 437.03 – 143.85−5.1% from high

Volume562.5K0.67× 20-day avg

Volatility · 60d63.8%Annualised

Short % of float15.2%3.8 days to cover

Net cash$819.9MCash $819.9M

Next earnings—Not scheduled

Split-adjusted performance

1W −5.1%1M +25.3%3M +25.6%6M +24.4%YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum84

Revenue growth—

Net margin—

Value (low P/E)—

Size91

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short3.7M−12.9% vs prior

Days to cover3.8Settled Oct 15

% of float15.2%

Short vol. 10d56.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
MANEVeradermics, Incorporated	$136.51	+2.17%	+24.4%	—	—	—	$5.70B
PTCTPTC Therapeutics	$68.97	+1.25%	+3.6%	+69.6%	−14.4%	—	$5.76B	Compare
COGTCogent Biosciences	$31.49	+1.38%	−12.2%	—	—	—	$5.46B	Compare
ERASErasca	$14.91	+1.84%	+36.8%	—	—	—	$5.21B	Compare
MIRMMirum Pharmaceuticals	$96.97	+11.42%	−11.9%	+39.6%	−22.0%	—	$6.30B	Compare
LGNDLigand Pharmaceuticals	$316.13	+0.83%	+35.9%	−31.8%	−36.2%	122.9	$6.32B	Compare
TVTXTravere Therapeutics	$52.42	+6.09%	+17.1%	+36.2%	−23.3%	—	$4.94B	Compare
IONSIonis Pharmaceuticals	$40.15	−0.67%	−47.8%	−40.7%	−42.8%	—	$6.67B	Compare
ORKAOruka Therapeutics	$101.41	+1.87%	+45.3%	—	—	—	$6.71B	Compare

News about Veradermics, Incorporated

All news →

No recent articles focused on Veradermics, Incorporated.

Quick answers

What does Veradermics, Incorporated do?: Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
What is MANE's market cap?: $5.70B, based on the Nov 4 close of $136.51.
Does Veradermics, Incorporated pay a dividend?: No regular cash dividend has been paid in the last year.
How much of MANE is sold short?: 3.7M shares, 15.2% of float, as of Oct 15, 2026.
What sector is MANE in?: Healthcare, in the Pharmaceuticals industry.

About Veradermics, Incorporated

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

HQ: New Haven, CT21 employeesListed Feb 4, 2026veradermics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology